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OBJECTIVE— Previous observational studies reported inconsistent results on the associa-
tion between diabetes and Parkinson’s disease, and data on the risk of developing incident
diabetes in relation to Parkinson’s disease are scarce. We aimed at comparing the diabetes
prevalence between patients with or without Parkinson’s disease and at exploring the risk of
developing incident diabetes associated with Parkinson’s disease.
RESEARCH DESIGN AND METHODS— We used the U.K.-based General Practice
Research Database (GPRD) to 1) compare the diabetes prevalence between Parkinson’s disease
cases and a matched comparison group free of Parkinson’s disease between 1994 and 2005 and
to 2) conduct a follow-up study with a nested case-control analysis to quantify the risk of
developing new-onset diabetes in association with Parkinson’s disease.
RESULTS— The diabetes prevalence was similar in patients with and without Parkinson’s
disease (adjusted odds ratio [OR] 0.95 [95% CI 0.80–1.14]). In the cohort analysis (incidence
rate ratio [IRR] 0.55 [95% CI 0.38–0.81]) and in the nested case-control analysis (adjusted OR
0.53 [95% CI 0.33–0.87]), the risk of developing diabetes was lower in patients with Parkinson’s
disease than in subjects without. The adjusted OR for patients with Parkinson’s disease who were
current levodopa users of five or more prescriptions was 0.22 (0.10–0.48) and was 1.11 (0.50–
2.45) for Parkinson’s disease patients not using levodopa.
CONCLUSIONS— In this observational study, diabetes prevalence was closely similar be-
tween patients with Parkinson’s disease and subjects without. The risk of developing incident
diabetes was lower for patients with Parkinson’s disease than for patients without, a finding that
was limited to Parkinson’s disease patients who were using levodopa.
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Idiopathic Parkinson’s disease is a com-mon neurodegenerative disease thatmay be related to mitochondrial dys-
function, oxidative stress, excitotoxicity,
apoptosis, and inflammation (1,2).
Chronic systemic inflammation, as well as
impaired mitochondrial metabolism,
have also been suspected of playing a role
in the development of type 2 diabetes (3–
5), and the possibility of a shared patho-
physiology of Parkinson’s disease and
type 2 diabetes has been put forth (6,7).
However, observational studies investi-
gating the association of these two disor-
ders are scarce. Two recent case-control
studies provided evidence for a possibly
reduced risk for Parkinson’s disease in di-
abetic patients (8,9), whereas others re-
ported a higher diabetes prevalence in
Parkinson’s disease patients (10,11), and
recent data from the Nurses Health Study
suggest that the risk of developing Parkin-
son’s disease does not differ between pa-
tients with or without diabetes (12). To
our knowledge, the risk of developing an
incident diagnosis of diabetes in Parkin-
son’s disease patients has not yet been
explored.
Studies from the 1970s described
Parkinson’s disease patients with hyper-
glycemia and hyperinsulinemia and
raised the proposition that levodopa may
be associated with an increased diabetes
risk (13,14), whereas bromocriptine in-
creased insulin sensitivity in an animal
model (15). We conducted a large popu-
lation-based study in two parts. The aim
of the first part was to assess the preva-
lence of diabetes in patients with newly
diagnosed Parkinson’s disease and to
compare it with patients without Parkin-
son’s disease. The aim of the second part
was to quantify the risk of new-onset di-
abetes in Parkinson’s disease patients and
to compare it with patients free of Parkin-
son’s disease, as well as to assess the pos-
sible role of anti-Parkinson medication on
the risk of developing an incident diabe-
tes diagnosis.
RESEARCH DESIGN AND
METHODS
Data source
We used the U.K.-based General Practice
Research Database (GPRD), which con-
tains computerized medical records of
5 million people who are registered
with selected general practitioners (16–
18). In the U.K., general practitioners are
responsible for primary health care, as
well as for referrals to specialists and for
hospitalizations (except in emergency sit-
uations). They record information on pa-
tient demographics (age, sex, weight, and
height), diagnoses, drug prescriptions, re-
ferrals, and hospital admissions, as well as
some lifestyle information (e.g., smoking
status). The recorded information on
drug exposure and on diagnoses in the
GPRD has been validated repeatedly and
proven to be of high quality (19,20). The
GPRD, one of the world’s largest data-
bases of anonymized patient records, is
managed by the Medicines and Health-
care products Regulatory Agency in the
U.K. The patients enrolled in the GPRD
are representative of the U.K. population
with regard to age, sex, geographic distri-
bution, and annual turnover rate (16),
and GPRD data have been used in previ-
ous studies on Parkinson’s disease (21–
25). The study protocol was reviewed and
approved by the Independent Scientific
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Advisory Committee (ISAC) for Medi-
cines and Healthcare Products Regula-
tory Agency Database Research. The
investigators had only access to anony-
mized information.
The base population consisted of all
patients in the GPRD who were aged40
years between 1 January 1994 and 31 De-
cember 2005. Within this base popula-
tion, we identified all patients with a
recorded first-time diagnosis of idio-
pathic Parkinson’s disease and, at ran-
dom, an equally sized comparison group
of subjects without Parkinson’s disease.
We matched this comparison group to
Parkinson’s disease patients on age (same
year of birth), sex, general practice (i.e.,
Parkinson’s disease patients and the com-
parison subject had to be enrolled with
the same general practitioner), date of the
first Parkinson’s disease diagnosis, and
years of history in the GPRD before this
Parkinson’s disease diagnosis date. Par-
kinson’s disease case subjects and patients
from the comparison group had to have at
least 3 years of medical history in the
computer record before the index date.
The Parkinson’s disease patients and the
one-for-one matched sample of Parkin-
son’s disease–free patients (i.e., the compar-
ison group) formed the study population.
We only included Parkinson’s disease
case subjects with an incident diagnosis of
“idiopathic Parkinson’s disease,” which
we defined as follows: Parkinson’s disease
case subjects must not have had more
than one prescription for an anti-
Parkinson medication recorded before
the index date, which was characterized
by the first recording of an OXMIS (Ox-
ford Medical Information System) code
342 (“Paralysis agitans”) or 342 D (“idio-
pathic parkinsonism”) or READ-codes
F12..00 (“Parkinson’s disease”), F12z.00
(“Parkinson’s disease NOS”), or F120.00
(“Paralysis agitans”); must not have re-
ceived any prescription for drugs known
to induce Parkinsonism (“typical” anti-
psychotic drugs, metoclopramide, or cin-
narizine) within 180 days before the
recorded Parkinson’s disease diagnosis;
and must have received at least two pre-
scriptions for anti-Parkinson drugs after
the index date in order to be eligible to be
included in the analysis.
Part 1: assessment of the diabetes
prevalence in Parkinson’s disease
patients and in the comparison
group
We assessed and compared the prevalence
of diabetes, demographic characteristics,
and a range of previously recorded diag-
noses of chronic diseases such as hyperlip-
idemia, asthma/chronic obstructive
pulmonary disease (COPD), dementia, and
various cardiovascular and neurological
diseases before the Parkinson’s disease diag-
nosis date (and the corresponding date in
the comparison group). We expressed rela-
tive risk estimates as odds ratios (ORs) with
95% CIs, and we adjusted the crude OR for
comorbidities in a multivariate conditional
logistic regression analysis.
Part 2: assessment of incident
diabetes in Parkinson’s disease
patients and in the comparison
group: cohort analysis
From the study population of Parkinson’s
disease case subjects and matched Parkin-
son’s disease–free comparison patients,
we excluded those with a history of dia-
betes before the first recorded Parkinson’s
disease diagnosis (or the corresponding
date in the matched comparison group),
as well as patients with a history of cancer,
HIV, alcoholism, or drug abuse. We fol-
lowed both the remaining newly diagnosed
Parkinson’s disease patients and the
matched Parkinson’s disease–free compari-
son group, from the start of the follow-up
date (i.e., the date of the Parkinson’s disease
diagnosis or the corresponding date in the
Parkinson’s disease–free comparison
group) and identified all patients in the
study population who developed new-
onset diabetes during follow-up. We accu-
mulated person-time from the start date
until a patient developed diabetes, died, the
medical record ended, or the end of the
study was reached (31 December 2005),
whichever came first. The date when a case
subject had the first-time diagnosis of dia-
betes recorded will be referred to as the “in-
dex date.” To be included in the analysis as
a valid incident diabetes case subject, a pa-
tient had to have a documented code for
diabetes recorded and must have either re-
ceived treatment with antidiabetes drugs
(insulin or oral antidiabetes drugs or both)
after the date of the first diabetes diagnosis,
or if no antidiabetes drug use was recorded
in the medical record, notes such as “dia-
betic on diet only” had to be recorded by the
general practitioner. If no treatment and no
diet recommendation were recorded, we
excluded the case. If a potential case had
antidiabetes treatment recorded shortly be-
fore the index date, we included the case
subject and corrected the index date. If a
case subject had a long-standing history of
antidiabetes drug use before the index date
and/or if the index date was not clear for
other reasons, we excluded the case subject.
For the purpose of this case subject valida-
tion, we manually reviewed computer
records of all potential case subjects,
blinded to the subject’s exposure status (i.e.,
Parkinson’s disease or non–Parkinson’s dis-
ease group). We assessed incidence rates
(IRs) of first-time diagnosed diabetes in the
population with Parkinson’s disease and in
the Parkinson’s disease-free comparison
group, and we calculated relative risk esti-
mates with 95% CIs by comparing diabetes
IRs between Parkinson’s disease patients
and the comparison group.
Nested case-control analysis
To identify potential risk factors for dia-
betes, to adjust the analysis on the associ-
ation between Parkinson’s disease and the
risk of developing diabetes for such po-
tential confounders, and to stratify Parkin-
son’s disease patients by anti-Parkinson
medication used, we conducted a nested
case-control analysis. We identified, at ran-
dom, for each incident diabetes case subject
up to four control patients from the study
population who did not develop diabetes,
and we matched these control subjects to
case subjects based on age (3 years), sex,
and calendar time. Control subjects had to
be alive at the index date. We assessed for all
diabetes case subjects and their control sub-
jects whether they had Parkinson’s disease
or not, what anti-Parkinson medication (if
any) they were using before the index date,
how many prescriptions they had, and at
what point in time the last prescription was
recorded before the index date. If the last
prescription was recorded within 90 days
before the index date, the patient was a “cur-
rent user,” and if this was3 months before
the index date the patient was a “past user.”
We also assessed smoking status (non-
smoker, current smoker, ex-smoker, or un-
known), BMI (25, 25–29.9,30 kg/m2,
or unknown), as well as recorded chronic
diseases such as hypertension, hyperlipid-
emia, or ischemic heart disease. We con-
ducted conditional logistic regression
analyses to explore the relative risk of de-
veloping a diabetes diagnosis in associa-
tion with previously recorded Parkinson’s
disease, expressed as ORs with 95% CIs,
and adjusted this analysis by the parame-
ters described above. In addition, since
-blockers, diuretics, and systemic ste-
roids are known to be associated with an
increased diabetes risk, we also assessed
the number and the timing of previous
prescriptions for these drugs and com-
pared such drug use before the index date
between diabetes case and control sub-
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jects. Furthermore, we stratified the main
analysis on the Parkinson’s disease–
diabetes association by age, sex, and anti-
Parkinson medication used. All statistical
analyses were performed with SAS soft-
ware, version 9.1 (SAS Institute, Cary, NC).
RESULTS— The study population en-
compassed 7,274 subjects (3,637 Parkin-
son’s disease case subjects and 3,637
matched subjects in the comparison
group free of Parkinson’s disease), of
which 60% were men. Approximately
90% of the Parkinson’s disease case sub-
jects had their first Parkinson’s disease di-
agnosis recorded after the age of 60 years.
Part 1: assessment of the diabetes
prevalence in Parkinson’s disease
patients and in the comparison
group
A prevalent diagnosis of diabetes was re-
corded in 291 (8%) of Parkinson’s disease
case subjects and in 308 (8.5%) of patients
free of Parkinson’s disease, yielding an OR
of 0.95 (95% CI 0.80–1.14), adjusted for
BMI, smoking, asthma/COPD, dementia,
hypertension, ischemic heart disease, con-
gestive heart failure, stroke/transient isch-
emic attack, arrhythmia, hyperlipidemia,
epilepsy, affective disorders, schizophrenia,
and neurotic and somatoform disorders.
Part 2: assessment of incident
diabetes in Parkinson’s disease
patients and in the comparison
group: cohort analysis
During follow-up, we identified 106 pa-
tients with an incident diabetes diagnosis
who met the inclusion criteria as de-
scribed above. Based on the specific codes
used by the general practitioner and on
the treatment pattern, all had type 2 dia-
betes; of these, 35 (33%) had a prior Par-
kinson’s disease diagnosis and 71 (67%)
had no history of Parkinson’s disease,
yielding a crude relative risk of 0.55 (95%
CI 0.38–0.81) for Parkinson’s disease pa-
tients compared with patients in the com-
parison group. The results of the person-
time analyses are displayed in detail in
Table 1.
Nested case-control analysis
Patient characteristics of 106 diabetic case
subjects and their 424 matched control
subjects in the nested case-control analy-
ses are displayed in Table 2. A previous
history of Parkinson’s disease was associ-
ated with a decreased risk of developing
an incident diabetes diagnosis (OR 0.53
[95% CI 0.33–0.87]), adjusted for age,
sex, and calendar time (by matching) and
for BMI, smoking status, hypertension,
ischemic heart disease, hyperlipidemia,
exposure to systemic steroids, -block-
ers, or diuretics in the multivariate model.
The diabetes risk for patients with Parkin-
son’s disease tended to be slightly higher
in men than in women, and stratification
by age resulted in a reduced risk for pa-
tients aged 75 years (Table 3). Both P
values for effect modification were
0.25.
We further stratified Parkinson’s dis-
ease patients by use of anti-Parkinson
medication before the diabetes diagnosis.
The adjusted OR for developing diabetes
for Parkinson’s disease patients with cur-
rent levodopa exposure of more than five
prescriptions before the diabetes diagno-
sis was 0.22 (95% CI 0.10–0.48), com-
pared with patients without Parkinson’s
disease (and therefore no levodopa use).
The adjusted OR for Parkinson’s disease
patients not receiving levodopa before the
diabetes diagnosis was 1.11 (0.50–2.45),
compared with patients without Parkin-
son’s disease (Table 3). A direct compari-
son between Parkinson’s disease patients
with current levodopa use with the refer-
ence group of Parkinson’s disease patients
without levodopa use yielded an OR of
0.30 (0.13–0.72). There were too few
prescriptions for other anti-Parkinson
drugs to conduct further analyses on their
effects.
CONCLUSIONS— In the first part of
this large primary care–based observa-
tional study, the prevalence of diabetes at
the date of the first-time Parkinson’s dis-
ease diagnosis was closely similar to a ran-
domly selected, matched comparison
group of patients without diagnosed Par-
kinson’s disease (OR 0.95 [95% CI 0.80–
1.14]). Two recent case-control studies
(8,9) also explored the association between
diabetes and Parkinson’s disease. In one
study (8), encompassing 352 Parkinson’s
disease case subjects and 484 control sub-
jects, the risk for Parkinson’s disease was
significantly reduced in men with a pre-
vious diabetes diagnosis (OR 0.52 [0.28–
0.97]) but not in women (0.80 [0.35–
1.83]). The authors of the second study
(9), a hospital-based, case-control analy-
sis including 178 Parkinson’s disease case
subjects and 533 control subjects, re-
ported a substantially lower diabetes
prevalence in Parkinson’s disease case
subjects (3.4%) than in control subjects
(10.9%), yielding a crude OR of 0.30
(0.13– 0.72). The authors (9) stated,
however, that the OR was no longer sta-
tistically significantly reduced when they
applied a multivariate analysis, but they
did not provide more details. In contrast,
a prospective follow-up study (11) in Fin-
land identified 633 incident Parkinson’s
disease case subjects and found an in-
creased risk of developing Parkinson’s
Table 1—Number of diabetic case subjects and IRs per 1,000 person-years, stratified by age and sex
Patients with Parkinson’s disease diagnosis Patients without Parkinson’s disease
IRR (95% CI)n
Person-
years IR (95% CI) n
Person-
years IR (95% CI)
All 35 11,307.4 3.10 (2.23–4.30) 71 12,679.1 5.60 (4.44–7.06) 0.55 (0.38–0.81)*
Men 23 6,605.6 3.48 (2.32–5.22) 42 7,327.0 5.73 (4.24–7.74) 0.61 (0.38–0.99)†
Women 12 4,701.9 2.55 (1.46–4.46) 29 5,352.1 5.42 (3.78–7.77) 0.47 (0.26–0.87)‡
Age (years)
40–49 — 125.5 — — 122.0 — —
50–59 2 752.8 2.66 (0.73–9.63) 9 738.4 12.19 (6.43–23.00) 0.22 (0.07–0.71)§
60–69 10 2,331.9 4.29 (2.33–7.88) 14 2,365.3 5.92 (3.53–9.91) 0.73 (0.33–1.61)§
70–79 14 4,480.7 3.12 (1.86–5.24) 28 4,899.2 5.72 (3.96–8.25) 0.55 (0.30–1.00)§
80 9 3,616.5 2.49 (1.31–4.72) 20 4,554.3 4.39 (2.84–6.77) 0.57 (0.27–1.18)§
*Compared with all patients without Parkinson’s disease. †Compared with male patients without Parkinson’s disease. ‡Compared with female patients without
Parkinson’s disease. §Compared with control subjects of the same age-group.
Diabetes and idiopathic Parkinson’s disease
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disease in diabetic subjects compared
with patients without diabetes (hazard ra-
tio 1.85 [95% CI 1.23–2.80]). A higher
prevalence of diabetes has also been re-
ported in Parkinson’s disease patients in a
cross-sectional survey (10). Finally, a re-
cent prospective analysis of data from the
Nurses’ Health Study and the Health Pro-
fessionals Follow-up Study encompass-
ing 530 incident Parkinson’s disease case
subjects found no evidence for a differ-
ence in the risk of developing Parkinson’s
disease between patients with and with-
out diabetes (relative risk 1.04 [95% CI
0.74–1.46]) (12), a finding that is consis-
tent with our observation. Thus, previous
studies exploring the association between
diabetes and Parkinson’s disease risk pro-
duced inconsistent results, whereby the
methodology of these studies differed sub-
stantially. Furthermore, most of these
studies were rather small in size with case
groups of 200–500 patients, while our
study encompassed a much larger Parkin-
son’s disease population.
A potential confounder of the associ-
ation between diabetes and Parkinson’s
disease risk may be obesity. While obesity
is a well-known risk factor for type 2 dia-
betes (26), results from observational stud-
ies on the association between obesity and
Parkinson’s disease are ambiguous. Authors
of a large U.S.-based observational study
(27) concluded that their findings did not
support a role of obesity in the Parkin-
son’s disease pathogenesis, but others re-
ported an association between obesity
and an increased Parkinson’s disease risk
in observational studies (28,29). In our
analysis, the BMIs of Parkinson’s disease
patients and Parkinson’s disease–free
control subjects did not differ substan-
tially at the date of the first Parkinson’s
disease diagnosis or the corresponding
date in the Parkinson’s disease–free com-
parison group. Compared with the refer-
ence group of subjects with a BMI 25
kg/m2, the relative risk estimates of devel-
oping Parkinson’s disease for subjects
with a BMI of 25–29.9 kg/m2 (OR 1.00
[95% CI 0.89–1.13]) or of 30 kg/m2
(0.88 [0.74–1.05]) were close to 1.0.
We not only assessed the association
between diabetes and the risk of develop-
ing Parkinson’s disease (part 1) but also of
developing new-onset diabetes associated
with a previous Parkinson’s disease diag-
nosis (part 2). To our knowledge, the as-
sociation between Parkinson’s disease
and the risk of developing a subsequent
incident diabetes diagnosis has not been
studied before. The findings of the
present analysis suggest that incident di-
abetes occurs less frequently in patients
with Parkinson’s disease compared with
those without Parkinson’s disease (OR
0.53 [95% CI 0.33–0.87]). The substan-
tial diabetes risk reduction seen in associ-
ation with Parkinson’s disease was driven
by levodopa users, while the risk for devel-
oping diabetes was not altered for Parkin-
son’s disease patients not using levodopa.
We cannot tell whether this finding points
to a causal association, whether it is the re-
sult of some bias, or whether it is a chance
finding. It is in some contrast to a report
from the 1970s in which levodopa was
orally administered for 1 year to 23 patients
and caused substantially impaired glucose
tolerance in the majority of these patients
(14). The authors explained their findings
by a possibly increased glycogenolysis and
Table 2—Distribution of characteristics and comorbidities in case and control subjects in the
nested case-control analysis
Characteristics
Diabetic case
subjects Control subjects Adjusted OR (95% CI)*
n 106 424
Age (years)
40–59 11 (10.4) 39 (9.2) —
60–79 66 (62.3) 266 (62.7) —
80 29 (27.3) 119 (28.1) —
Sex
Male 65 (61.3) 260 (61.3) —
Female 41 (38.7) 164 (38.7) —
Smoking status
Nonsmoker 56 (52.8) 243 (57.3) 1.00 (referent)
Current smoker 9 (8.5) 47 (11.1) 0.94 (0.39–2.27)
BMI (kg/m²)
25 16 (15.1) 141 (33.3) 1.00 (referent)
25–29.9 42 (39.6) 135 (31.8) 2.52 (1.23–5.17)
30 28 (26.4) 46 (10.9) 3.80 (1.74–8.30)
Comorbidities
IHD 50 (27.2) 163 (22.2) 1.30 (0.69–2.46)
Hypertension 58 (54.7) 144 (34.0) 1.49 (0.79–2.79)
Dyslipidemia 18 (17.0) 43 (10.1) 1.40 (0.63–3.11)
Prior drug use†
-Blockers 26 (24.5) 55 (13.0) 1.44 (0.70–2.93)
Diuretics 47 (44.3) 88 (20.8) 2.79 (1.41–5.53)
Systemic steroids 8 (7.6) 12 (2.8) 6.66 (2.04–21.72)
Data are n (%), unless otherwise indicated. *Adjusted for covariates in this Table. †Most recent drug
prescription within 3 months before the index date and five or more prescriptions in total.
Table 3—Risk of diabetes in the nested case-control analysis
Parameter
Case
subjects (%)
Control
subjects (%)
Adjusted
OR (95% CI)*
n 106 424
No Parkinson’s disease 71 (67.0) 209 (49.3) 1.00 (referent)
Parkinson’s disease 35 (33.0) 215 (50.7) 0.53 (0.33–0.87)
Men 23 (65.7) 136 (63.3) 0.57 (0.30–1.08)
Women 12 (34.3) 79 (36.7) 0.34 (0.13–0.91)
Age (years)
40–74 18 (51.4) 121 (56.3) 0.44 (0.21–0.91)
75 17 (48.6) 94 (43.7) 0.71 (0.33–1.56)
No use of levodopa 13 (37.1) 47 (21.9) 1.11 (0.50–2.45)
Current use of levodopa† 11 (31.4) 131 (60.9) 0.22 (0.10–0.48)
Any other use of levodopa‡ 11 (31.4) 37 (17.2) 0.88 (0.42–1.81)
Data are n (%), unless otherwise indicated. *Adjusted for covariates from Table 2. †Five or more prescrip-
tions before the diabetes diagnosis. ‡Current use of less than five prescriptions or past use.
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inhibition of peripheral glucose utilization
caused by levodopa. This result was not
confirmed by other authors (13) who ex-
posed patients with levodopa for at least 3
months, which lead to a slight improve-
ment of the fasting serum glucose and insu-
lin sensitivity. However, the study was small
and the observed effect did not reach statis-
tical significance (13).
Our study has several limitations.
Both Parkinson’s disease and diabetes are
diseases of slow onset, and, therefore, the
onset of disease precedes the actual diag-
nosis date recorded in the database
(which we used as the index date). For
this reason, we only included Parkinson’s
disease patients who did not have anti-
Parkinson medication before the first di-
agnosis date to reduce the likelihood of
including prevalent case subjects with a
longer-term history of Parkinson’s disease
symptoms. In addition, we only included
diabetes case subjects in the follow-up
portion of the study whose medical
records provided evidence that the diag-
nosis was incident (i.e., followed by a
newly introduced antidiabetes treat-
ment). It is further possible that we did
not capture all diabetes case subjects dur-
ing follow-up since diabetes may go un-
detected due to the lack of specific clinical
symptoms. Ideally, this may have oc-
curred at random (i.e., regardless of a pre-
vious Parkinson’s disease diagnosis),
leading to a risk reduction toward to null.
However, it is also possible that the like-
lihood of detecting diabetes did not occur
at random but was dependent on disease
status and therefore to some degree on
medical attention. In this latter case, how-
ever, one might rather expect higher med-
ical awareness in Parkinson’s disease case
subjects than in the comparison group of
patients free of Parkinson’s disease, which
would have biased toward an increased
diabetes risk. We adjusted the nested
case-control analysis for BMI, various
chronic diseases, and various drugs that
reflect overall morbidity and that are
known risk factors for diabetes. These ad-
justments did not materially change the
association between Parkinson’s disease
and the risk of developing new-onset
diabetes.
In summary, the findings of the first
part of this observational study suggest
that the prevalence of diabetes does not
substantially differ between patients with
newly diagnosed Parkinson’s disease and
subjects without Parkinson’s disease. The
results of the second part suggest that the
risk of developing an incident diabetes di-
agnosis tends to be lower in Parkinson’s
disease patients than in subjects without
Parkinson’s disease. This effect was lim-
ited to Parkinson’s disease patients who
used levodopa.
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